Akatinol Memantin

General characteristics. Structure:

Active ingredient: 10 mg of a memantin of a hydrochloride.

Excipients: lactose, cellulose microcrystallic, silicon dioxide colloid, talc, magnesium stearate.

Pharmacological properties:

Pharmacodynamics. Being a non-competitive antagonist N-methyl-D-aspartate (NMDA) - receptors, has the modulating effect on glutamatergichesky system. Regulates ionic transport, blocks calcium channels, normalizes membrane potential, improves process of transfer of nervous impulse. Improves cognitive processes, increases daily activity.

Pharmacokinetics. After intake it is quickly and completely soaked up. The maximum concentration in a blood plasma is reached within 2–6 hours. At normal function of kidneys of cumulation of drug it is noted. Removal proceeds dvukhfazno. The elimination half-life makes in the first phase — 4–9 h, in the second phase — 40–65 h. It is removed with urine.

Indications to use:

Dementia of altsgeymerovsky type, vascular dementia, the mixed dementia of all severity.

Route of administration and doses:

Inside, during food. The mode of dosing is set individually. It is recommended to begin treatment with purpose of minimum effective doses.

The adult at dementia appoint within 1 week of therapy in a dose 5 mg/days, within the 2nd week — in a dose of 10 mg/days. Within the 3rd week — in a dose of 15-20 mg/days. If necessary perhaps further weekly increase in a dose on 10 mg before achievement of a daily dose of 30 mg.

The optimum dose is reached gradually, at increase in a dose every week.

Features of use:

At patients with Alzheimer's disease at a stage of moderate and heavy dementia ability to driving of motor transport and control of difficult mechanisms is usually broken.

Besides, мемантин can cause change of speed of response therefore at the patients receiving treatment in out-patient conditions it is necessary to observe extra care during the driving of motor transport or control of mechanisms.

Side effects:

Side reactions are classified by clinical manifestations ( according to defeat of certain systems of bodies) and by occurrence frequency: very often (≥ 1/10), it is frequent (≥1/100 to <1/10), is not frequent (≥ 1/1,000 to ≤ 1/100), is rare (≥1/10,000 to ≤ 1/1,000), is very rare (≤ 1/10,000), frequency is not established ( now data on prevalence of side reactions are absent).

From an organism in general – the general side reactions	Often Seldom	Headache Fatigue
Infections	Seldom	Fungal infections
Mental disturbances	Often Seldom Seldom Frequency is not established	Drowsiness Confusion of consciousness Gallyutsinatsii1 Psychotic reaktsii2
Disturbances from outside cardiovascular system	Seldom Seldom	Hypertensia Venous thrombosis / thromboembolism
Gastrointestinal disturbances	Often Seldom Frequency is not established	Lock Nausea, vomiting Pankreatit2
Disturbances from the central and peripheral nervous system	Often Seldom Very seldom	Dizziness Gait disturbance Spasms

1 Hallucinations were observed, mainly, at patients with Alzheimer's disease at a stage of heavy dementia.

2 There are separate messages on emergence of these side reactions at use of drug in clinical practice (the data obtained after emergence of drug on sale).

Interaction with other medicines:

At simultaneous use with the drugs L-dopy, dopamine agonists, anticholinergics action of the last can amplify.

At simultaneous use with barbiturates, neuroleptics action of the last can decrease. At combined use can change (to strengthen or reduce) action of a dantrolen or Baclofenum therefore doses of drugs should be selected individually.

It is necessary to avoid simultaneous appointment with amantadiny, Ketaminum and deksametofany.

Increase in plasma of levels of Cimetidinum, procaineamide, Kinidinum, kinin and nicotine at a concomitant use is possible with memantiny.

Decrease in level of Hydrochlorthiazidum at a concomitant use is possible with memantiny.

Contraindications:

Individual hypersensitivity to drug, the expressed renal failures, pregnancy, breastfeeding, children up to 18 years ( in connection with insufficiency of data).

With care appoint a sick thyrotoxicosis, epilepsy, spasms ( including in the anamnesis), at a myocardial infarction, heart failure.

Overdose:

Symptoms: strengthening of expressiveness of side effects.

Treatment: gastric lavage, reception of absorbent carbon, symptomatic therapy.

Storage conditions:

At a temperature not above 25 °C in the places unavailable to children. Period of validity 4 years. Not to use upon termination of a period of validity.

Issue conditions:

According to the recipe

Packaging:

Tablets, film coated, 10 mg. On 10 tablets in the blister from a film of polyvinyl chloride and aluminum foil. 3 or 9 blisters together with  the application instruction place in a cardboard pack.